Manchester Medical Society joint meeting with the Royal Society of Medicine

Manchester Medical Society 175 Years— A Nobel Celebration

CPD Applied

Wednesday 21st October 2009 at 2.00 pm
Lecture Theatre 2, Stopford Building,
The University of Manchester, Oxford Road,
Manchester, M13 9PT

Introduction

Dear Colleague

2009 marks an important date in the annals of the Manchester Medical Society, namely its 175th anniversary. On 4th September 1834 it was formally founded at a public meeting of the physicians, surgeons and apothecaries of Manchester, Salford and neighbourhoods, which was especially called for the purpose. An equally interesting event occurred a month later on Wednesday 1st October 1834 when the first formal meeting of the newly constituted Society was held.

This celebratory symposium is timed to occur in the 175th anniversary month and year, namely October 2009. To commemorate the anniversary, we have drawn together a group of extremely distinguished physicians and scientists who have made outstanding contributions to the advancement of medical sciences including Professor Sir Tim Hunt, Nobel Prize Winner in Physiology/Medicine 2001. The speakers will describe how our understanding of the fundamentals of cell cycle control was elucidated and is important for new therapeutic approaches in cancer: how application of principles of developmental biology and cell culture can lead to new regenerative medicines (including cultured chondrocytes for joint resurfacing – ChondroCelect, the first cell based human product to be centrally approved by the European Medicines Evaluation Agency (EMEA) under the new Advanced Therapy Medicinal Products legislation in June 2009) the importance of parasites and poverty in global health problems and how knowledge of the role of key cytokines in health and disease has lead to major new medicines – the TNFα blockers – for Rheumatoid Arthritis, Crohn's disease, Psoriasis etc and is leading to the development of novel tolerizing vaccines. This will be followed by my Presidential address, which will continue the theme of application of basic science to developing new human therapeutics by describing the phenomenon of scar free healing in the embryo and how elucidation of the underlying cellular and molecular mechanisms has lead to a new range of potential pharmaceuticals to prevent or reduce scarring in man.

We look forward to welcoming many existing and new members to meetings of the Society in 2009/2010. Each of the ten sections has an exciting and relevant programme, whilst the main Society programme features a joint meeting with the Medico Legal Society in November on Illness, Deception and Malingering, the Christmas Lecture for young people in December, to be given by Lord Robert Winston (whose many films, TV documentaries, published books as well as his distinguished contributions to Reproductive Medicine are well known), a symposium on fibrotic diseases and scars (of the lung, kidney, liver and CNS) in January followed by the Telford Memorial Lecture to be delivered by Professor Michele De Luca from Italy, who will describe his pioneering work on using cultured epidermal stem cells in life saving treatment of massive full thickness burn patients, genetically engineered cultured autologous keratinocytes to restore the skin of infants with Epidermolysis Bullosa and the use of cultured Limbal stem cells to regenerate the cornea and restore vision following eye injury. The joint meeting with the Liverpool Medical Institution in March will feature presentations by Professor Gus McGrouther and Professor Ralf Paus, both of the University of Manchester covering Plastic Surgery and Hair respectively. March will also see a new event in the Society's calendar, namely an afternoon meeting for medical students featuring talks by prominent Manchester Biomedical researchers and detailed career advice. The John Wilkinson Memorial Lecture will be delivered in May by Dr George Poste, FRS from the University of Arizona, covering the important topic of the convergence of clinical medicine, engineering and computing: new horizons in healthcare delivery. George is an outstanding speaker and was formerly Research & Development Director of SmithKline Beecham Pharmaceuticals and Chair of the US Government's task force on Bioterrorism. I do hope the Society's programme has wide appeal and I look forward to seeing many of you at our upcoming meetings.

Professor Mark WJ Ferguson

Speakers

Sir Tim Hunt, FRS— Nobel Prize winner 2001, Principal Scientist, Cancer Research UK

"The Cell Cycle and Cancer"

Sir Tim Hunt was born in Neston, Cheshire to Richard Hunt, a lecturer in Palaeography in Liverpool and Kit Rowland, daughter of a timber merchant. Educated in Oxford and at Clare College, Cambridge, his early work in America and Cambridge focussed on protein synthesis in reticulocytes, but in 1982 when working at the Marine Biology Laboratory at Woods Hole, Massachusetts on sea urchin eggs, he discovered the cyclin molecules: an important set of regulators of the cell cycle in vertebrate cells. Since 1990, he has worked at the Imperial Cancer Research Fund, now known as the Cancer Research UK, London Research Institute. He was made a Fellow of the Royal Society in 1991, Foreign Associate of the US National Academy of Sciences in 1999 and in 2001 he was awarded the Nobel Prize in Physiology/Medicine (jointly with Lee Hartwell and Paul Nurse) for their discoveries regarding cell cycle regulation by cyclin and cyclin dependent kinases. In 2006 he was awarded the Royal Medal for 'discovering a key aspect of cell cycle control, the protein cyclin, which is a component of cyclin dependent kinases demonstrating his ability to grasp the significance of the result outside his immediate sphere of interest'. He was Knighted by the Queen in the same year. Dr Hunt has written two books, numerous papers, serves on the scientific advisory panel of many institutions and is chairman of the European Molecular Biology Organisation (EMBO).

Professor Frank Luyten – Chairman of the Division of Rheumatology and Department of Musculoskeletal Sciences at the University Hospitals, Leuven, Belgium.

"Regenerative Medicine: the creation of a biological spare part by developmental engineering"

Frank Luyten has extensive experience in the field of cell and developmental biology of skeletal tissue with a specific focus on joint disorders. His scientific achievements include the discovery of cartilage derived morphogenetic proteins, members of the BMP family and their role in human skeletogenesis and the discovery of Frzb, an antagonist of Wnt signaling. Both pathways are critical in the formation of skeletal tissues and joint morphogenesis as well as in human arthritic diseases. Professor Luyten is also the Co-founder, Scientific and Medical Advisor and Director of TiGeniX, a biotechnology spin-out company from the Universities of Leuven and Ghent, specialising in regenerative medicine. In June 2009 ChondroCelect, a regenerative, autologous medicinal product indicated for the repair of full thickness cartilage lesions of the knee, received a positive opinion from the European Medicines Agency and is the first cell based product to be centrally approved in Europe under the new Advanced Therapy Medicinal Products legislation. The paper describing the pivotal clinical trial of this product, published in the February 2008 issue of the American Journal of Sports Medicine, won the prestigious Hughston Award. Application of the principles of developmental biology and cell culture define a new field of 'Regenerative Medicine' providing the promise of medical therapies for many diseases.

Frank Luyten holds a medical degree (1980) and PhD (1986) from the University of Ghent and obtained his Board Certification in Rheumatology in 1986. From 1986 to 1992 he was a visiting scientist at the National Institutes of Health, Bethesda, Maryland, USA and from 1992 to 1997 Head of the Developmental Biology Unit of the Craniofacial and Skeletal Diseases Branch at the National Institute of Dental and Craniofacial Research in Bethesda, USA. He has been Professor in the Faculty of Medicine of the Katholieke Universitat, Leuven, since 1997.

Speakers

Professor Lord May of Oxford, FRS (Professor of Zoology, University of Oxford)

"Parasites, people and poverty: Infectious disease and millennium development goals"

This presentation will briefly review past history and present patterns in the interactions between parasites (defined broadly to include viruses and bacteria along with protozoan, helminth and arthropod parasites) and human populations, in developed and developing countries. Against this background Lord May shall offer some thoughts on current public health initiatives, at national and international levels, with particular reference to the Millennium Development Goals. The news is both good and bad; mortality and morbidity from infectious diseases in the developing world are significantly lower than they were 50 years ago, but we should and could be doing better, particularly in relation to neglected tropical diseases.

Lord May holds a Professorship jointly at Oxford University and Imperial College, London and is a Fellow of Merton College, Oxford. He was until recently President of the Royal Society (2000-2005), and before that Chief Scientific Adviser to the UK Government and Head of the UK Office of Science and Technology (1995-2000). His career includes a Personal Chair in Physics at Sydney University aged 33, Class of 1877 Professor of Zoology and Chairman of the Research Board at Princeton, and in 1988 a move to Britain and Oxford as Royal Society Research Professor. Particular interests include: how populations are structured and respond to change, particularly with respect to infectious diseases and biodiversity. He has received numerous research awards including the Royal Swedish Academy's Crafoord Prize, Swiss-Italian Balzan Prize, Japanese Blue Planet Prize and an award by the McArthur Foundation, USA. He was awarded a Knighthood in 1996, and appointed a Companion of the Order of Australia in 1998, both for services to science. In 2001 he was one of the first 15 Life Peers created by the "House of Lords Appointments Commission". In 2002, The Queen appointed him to the Order of Merit (the fifth Australian in its 100-year history). In 2007 he received the Royal Society's Copley Medal, its oldest (1731) and most prestigious award, given annually for "outstanding achievements in research in any branch of science".



Professor Marc Feldmann FRS (Head, Kennedy Institute of Rheumatology, Imperial College London).

"Anti TNF and the emergence of anti-cytokine therapy"

Professor Feldmann's research focuses on molecular mechanisms of auto immune diseases with a special interest in the role of cytokines. In immunology, research interests focus on signalling pathways and dendritic cells: this work has lead to the development of novel tolerising or immunising vaccines for auto immune and other disease. In cytokine research, Marc Feldmann is internationally renowned for his work on the mechanisms of chronicity in diseases: why the cytokine pathways are stuck on, rather than switching off, as they do in normal cells. These interests have lead to new treatments for a number of diseases including Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriasis and Psoriatic Arthritis based on blockade of the TNF alpha pathway. Much of this research has involved close interactions with various pharmaceutical and biotechnology companies, such that drugs to block the TNF alpha pathway are major block-busters bringing benefit to millions of patients. Professor Feldmann has received numerous important international research awards including, the Crafoord Prize from the

Speakers

Royal Swedish Academy in 2000, the Albert Lasker Award for Clinical Medical Research, USA in 2003, the Cameron Prize in 2004 and the Dr Paul Janssen Award for Biomedical Research in 2008. Professor Marc Feldmann was awarded the European Inventor of the Year award in 2007 in the Lifetime Achievement category.

Marc Feldmann graduated with a Medical Degree from the University of Melbourne in 1967 and a PhD in Immunology from the Walter and Eliza Hall Institute of Medical Research in 1972. He is a Fellow of the Royal College of Physicians and The Royal College of Pathologists. He was elected a Fellow of the Royal Society of London, the Academy of Medical Sciences and several national academies.

Professor Mark WJ Ferguson – Co-founder and Chief Executive Officer, Renovo: Professor, Faculty of Life Sciences, University of Manchester.

'Scar Wars: from accidental discovery of scar free embryonic healing to potential human pharmaceutical'

In the late 1980's we discovered, by accident, that surgical incisions made on early mammalian embryos healed perfectly with no scar. Scarring is a major medical problem in many organs and tissues of the body causing adverse functional, aesthetic and psychological sequelae. Investigation of the cellular and molecular mechanisms underlying scar free and scar forming healing identified a number of pathways which could be manipulated in the adult to prevent or reduce scarring. One of these, TGFβ3 (Avotermin, Juvista) has now been administered to more than 1,500 human subjects in a series of double blind, placebo controlled clinical trials, which have shown statistically significant efficacy in the prevention and reduction of scarring in the skin.

Mark Ferguson is the Co-founder and Chief Executive Officer of Renovo, a biotechnology company listed on the London Stock Exchange, and a Professor in the Faculty of Life Sciences at the University of Manchester, where he served previously as Dean and Head of Department. He has wide ranging research interests, including developmental biology, particularly of the face and the birth defect cleft lip and palate, alligator and crocodile biology (where he discovered temperature dependent sex determination), wound healing and scarring. He has received numerous research awards and prizes including the 2002 European Science Prize. Mark Ferguson holds degrees in Anatomy and Embryology (BSc, PhD), Dentistry (BDS) and Medical Sciences (DMedSci) from the Queens University of Belfast, is a Fellow of the Royal College of Surgeons of Ireland and Edinburgh (FFD,FDS), a Founding Fellow of the Academy of Medical Sciences (FMedSci) and was made a Commander of the British Empire (CBE) for services to Health and Life Sciences.

Programme

1.30 pm Registration and Coffee

Chairman—Professor Mark Ferguson (President-elect, Manchester Medical Society)

2.00 pm The Cell Cycle and Cancer
Professor Sir Tim Hunt, FRS (Principal Scientist, Cancer Research UK)

2.40 pm Regenerative medicine: the creation of a biological spare part by developmental engineering
Professor Frank Luyten (Chairman of the Division of Rheumatology and Department of Musculoskeletal Sciences, University Hospitals, Leuven, Belgium)

3.20 pm **Coffee Break**

3.40 pm Parasites, people and poverty: infectious diseases and Millennium Development Goals
Professor Lord May of Oxford, FRS (Professor of Zoology, University of Oxford)

4.20 pm Anti TNF and the emergence of anti-cytokine therapy
Professor Marc Feldmann, FRS (Head, Kennedy Institute of Rheumatology, Imperial College London)

5.00 pm **Coffee Break**

5.30 pm Annual General Meeting of the Manchester Medical Society followed by the **PRESIDENTIAL ADDRESS of**
Professor Mark Ferguson (Co-founder and Chief Executive Officer, Renovo: Professor, Faculty of Life Sciences, University of Manchester)

Entitled **Scar Wars: from accidental discovery of scar free embryonic healing to potential human pharmaceutical**

6.45 for 7.15 pm Wine Reception and Presidential Dinner of the Manchester Medical Society in the Christie Bistro, Old Quadrangle, University of Manchester.

Directions and Parking

DIRECTIONS & PARKING

Located within the University of Manchester campus, the Stopford Building (Medical School) is situated on Oxford Road, next to the Holy Name Church. Lecture Theatre 2 is on the first floor.

By Road
All approach routes are clearly signposted 'Universities'.

From the North (M6):
Leave M6 via M61 and continue to M60. Join M60 and travel anti-clockwise to junction 12 and join M602. Join A57 Regent Road to A57(M) Mancunian Way. Coming up the underpass, indicate left from Chester A5103. At the first roundabout take the 2nd exit. At the next roundabout take the 3rd exit onto Cambridge Street (which becomes higher Cambridge Street). Turn left at the traffic lights into Booth Street West. Take first right into Booth Street West car park.

From M62:
Leave the M62 at junction 12 and join M602 Salford. Follow the directions as above from M602.

From the South (M6):
Leave M6 at junction 19 and onto the A556 for 3 miles. Join M56 at junction 8 heading towards Manchester Airport. Continue along M56 (which continues as A5103 Princess Road). Turn right into B5219 (Moss Lane East) by the Brewery. At the traffic lights, turn left onto Lloyd Street North, which continues onto Higher Cambridge Street. At the traffic lights, turn right onto Booth Street West and the car park is the first exit on the right.

Car parking is available in the paid public car parks at both the multi-storey car park on Booth Street West and the Manchester Aquatics Centre multi-storey on Booth Street East. Visitor car parking is also available at Manchester Royal Infirmary in the Grafton Street multi-storey car park.

By Air

Manchester International Airport is within easy reach of The University of Manchester (20 minutes by car or taxi). There is also a direct rail link to Piccadilly and Oxford Road railway stations.

By Rail

There are three train stations in Manchester – Piccadilly, Victoria and Oxford Road. The nearest station is Oxford Road. Trains run between Piccadilly and Oxford Road every few minutes. There is no convenient direct link between Victoria and Oxford Road. However, there are good taxi services from all three stations.

By Bus

From Piccadilly Train Station catch the 147.
From Piccadilly Bus Station catch any of the following: 14, 16, 41, 42, 43, 44, 48, 111, 140, 142, 157 and 250.

Booking Form

Joint MMS/RSM Symposium, Wednesday 21st October 2009
DELEGATE INFORMATION

Title: ***Professor / Dr / Mr / Mrs / Ms***	
Forename(s):	*Surname:*
Job Title:	*Place of Work:*
Address:	*Telephone:*
Postcode:	*E-mail:*

There is no registration fee to attend this meeting but to confirm attendance and assist with registration please complete and return this form.

I WISH TO ATTEND THE AFTERNOON SYMPOSIUM ON WEDNESDAY 21st OCTOBER 2009 ☐

Presidential Dinner
There is a cost to attend the Presidential Dinner which is being held in the Christie Bistro, Old Quadrangle, University of Manchester. A wine reception will be held at 6.45 pm followed by dinner at 7.15 pm. The cost to attend the Presidential Dinner is £50.00 per person including wine.

Please reserve ……places as I/we wish to attend the Presidential Dinner (£50 per person) ☐

Special Dietary Needs …….

I enclose a cheque for £……..made payable to *Manchester Medical Society* ☐

Please return this form to:

Manchester Medical Society, c/o John Rylands University Library, Oxford Road, Manchester, M13 9PP, **before Wednesday 14th October 2009**

Telephone 0161 273 6048, Fax 0161 272 8046, or email admin@mms.org.uk